MedCity News
DECEMBER 29, 2024
Through collaboration between regulators and healthcare stakeholders, telehealth prescribing can continue to expand treatment access while maintaining proven safety standards. The post Navigating Virtual Prescribing Policy Changes in 2025 appeared first on MedCity News.
Pharmaceutical Technology
DECEMBER 29, 2024
Nelistotug is under clinical development by GSK and currently in Phase II for Recurrent Head And Neck Squamous Cell Carcinoma.
MedCity News
DECEMBER 29, 2024
Remodel Health received $100 million in funding from Oak HC/FT and Hercules Capital. The post Remodel Health Secures Over $100M to Fuel Expansion in the ICHRA Market appeared first on MedCity News.
Pharmaceutical Technology
DECEMBER 29, 2024
Trastuzumab rezetecan is under clinical development by Jiangsu Hengrui Medicine and currently in Phase I for Head And Neck Cancer.
Advertisement
What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.
MedCity News
DECEMBER 29, 2024
Dr. Eric Topol pointed out that while initial findings on generative AI in clinical settings are promising, they may not withstand the complexities of real-world clinical practice. The post Dr. Eric Topol: Generative AI Studies Boast Promising Results, But Real-World Challenges Remain appeared first on MedCity News.
Pharmaceutical Technology
DECEMBER 29, 2024
Trastuzumab rezetecan is under clinical development by Jiangsu Hengrui Medicine and currently in Phase I for Transitional Cell Carcinoma (Urothelial Cell Carcinoma).
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
Pharmaceutical Technology
DECEMBER 29, 2024
GCC-4001 is under clinical development by Artiva Biotherapeutics and currently in Phase II for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma).
MedCity News
DECEMBER 29, 2024
These valuable caregivers do not need false claims, empty promises, or even more technology to stay on top of. They need access to health education and literacy, healthy food, and seamless self-efficacy tools. The post Despite Our Efforts, The Sandwich Generation is Still Missing These Key Ingredients appeared first on MedCity News.
Pharmaceutical Technology
DECEMBER 29, 2024
GCC-4001 is under clinical development by Artiva Biotherapeutics and currently in Phase II for Diffuse Large B-Cell Lymphoma.
MedCity News
DECEMBER 29, 2024
In this episode, were joined by Kathryn Schubert, president and CEO of the Society for Womens Health Research. Schubert discusses the trends in womens health that defined 2024 and what we can expect in the coming year. The post MedCity FemFwd: What the Future Holds for Women’s Health in 2025 appeared first on MedCity News.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Pharmaceutical Technology
DECEMBER 29, 2024
GCC-4001 is under clinical development by Artiva Biotherapeutics and currently in Phase I for Lupus Nephritis.
Pharmaceutical Technology
DECEMBER 29, 2024
GCC-4001 is under clinical development by Artiva Biotherapeutics and currently in Phase II for Follicular Lymphoma.
Pharmaceutical Technology
DECEMBER 29, 2024
GCC-4001 is under clinical development by Artiva Biotherapeutics and currently in Phase II for Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma).
Pharmaceutical Technology
DECEMBER 29, 2024
GCC-4001 is under clinical development by Artiva Biotherapeutics and currently in Phase II for Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy.
Advertisement
Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten
Pharmaceutical Technology
DECEMBER 29, 2024
GCC-4001 is under clinical development by Artiva Biotherapeutics and currently in Phase II for Peripheral T-Cell Lymphomas (PTCL).
Pharmaceutical Technology
DECEMBER 29, 2024
Nelistotug is under clinical development by GSK and currently in Phase II for Recurrent Head And Neck Squamous Cell Carcinoma.
Pharmaceutical Technology
DECEMBER 29, 2024
Trastuzumab rezetecan is under clinical development by Jiangsu Hengrui Medicine and currently in Phase I for Head And Neck Cancer.
Pharmaceutical Technology
DECEMBER 29, 2024
Trastuzumab rezetecan is under clinical development by Jiangsu Hengrui Medicine and currently in Phase I for Transitional Cell Carcinoma (Urothelial Cell Carcinoma).
Pharmaceutical Technology
DECEMBER 29, 2024
GCC-4001 is under clinical development by Artiva Biotherapeutics and currently in Phase II for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma).
Pharmaceutical Technology
DECEMBER 29, 2024
GCC-4001 is under clinical development by Artiva Biotherapeutics and currently in Phase II for Diffuse Large B-Cell Lymphoma.
Pharmaceutical Technology
DECEMBER 29, 2024
GCC-4001 is under clinical development by Artiva Biotherapeutics and currently in Phase I for Lupus Nephritis.
Pharmaceutical Technology
DECEMBER 29, 2024
GCC-4001 is under clinical development by Artiva Biotherapeutics and currently in Phase II for Follicular Lymphoma.
Advertisement
Quotas need to be hit. Revenue goals need to be met. This reality makes shortening sales onboarding time a top priority. Organizations with a standard onboarding process boost employee retention by 58% and increase productivity by 50%. Unfortunately, many companies struggle with inefficient processes that lead to high turnover and missed revenue opportunities.
Pharmaceutical Technology
DECEMBER 29, 2024
GCC-4001 is under clinical development by Artiva Biotherapeutics and currently in Phase II for Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma).
Pharmaceutical Technology
DECEMBER 29, 2024
GCC-4001 is under clinical development by Artiva Biotherapeutics and currently in Phase II for Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy.
Pharmaceutical Technology
DECEMBER 29, 2024
GCC-4001 is under clinical development by Artiva Biotherapeutics and currently in Phase II for Peripheral T-Cell Lymphomas (PTCL).
Expert insights. Personalized for you.
86 
Let's personalize your content